Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
-
- Neil P. Shah
- Department of Medicine/Hematology-Oncology, UCSF School of Medicine, San Francisco, CA, USA;
-
- Valentín García-Gutiérrez
- Servicio Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain;
-
- Antonio Jiménez-Velasco
- Hospital Universitario Carlos Haya, Malaga, Spain;
-
- Sarah Larson
- David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;
-
- Susanne Saussele
- III, Med. Clinic, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany;
-
- Delphine Rea
- Department of Hématologie, Hôpital Saint-Louis, Paris, France;
-
- François-Xavier Mahon
- Department of Hématologie, Institut Bergonié, University of Bordeaux, Bordeaux, France;
-
- Moshe Yair Levy
- Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA;
-
- María Teresa Gómez-Casares
- Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain;
-
- Fabrizio Pane
- Dipartimento di Medicina clinica e Chirurgia, Università degli Studi di Napoli Federico II, Naples, Italy;
-
- Franck-Emmanuel Nicolini
- Hématologie Clinique, Centre Léon Bérard, Lyon, France;
-
- Michael J. Mauro
- Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
-
- Oumar Sy
- Bristol-Myers Squibb, Princeton, NJ, USA;
-
- Patricia Martin-Regueira
- Bristol-Myers Squibb, Princeton, NJ, USA;
-
- Jeffrey H. Lipton
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
収録刊行物
-
- Leukemia & Lymphoma
-
Leukemia & Lymphoma 61 (3), 650-659, 2019-10-24
Informa UK Limited